Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $215.98 +3.92%
Revenue Growth %: +6.2%
Financial Fact:
Income from operations: 136.25M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Revenue Growth %: +6.2%
Financial Fact:
Income from operations: 136.25M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $3.58, $0.26 better than the analyst estimate of $3.32. Revenue for the quarter came in at $469.37 million versus the consensus estimate of $482.48 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2018 EPS of $12.75-$13.25, versus the consensus of $13.11. Jazz Pharmaceuticals sees FY2018 revenue of $1.86-1.9 million, versus the consensus of $1.92 million.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Federal Realty Inv. Trust (FRT) Tops Q3 EPS by 3c ; Offers Guidance
- Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 1c, Misses on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
